Services offered by the Vaccine Evaluation and Development Centre (VDEC)

AI Summary

The Vaccine Development and Evaluation Centre (VDEC), part of the UK Health Security Agency (UKHSA), provides specialized support for vaccine and therapeutic development across all stages. Working with industry, government, and academic partners, VDEC operates under a regulatory framework that includes ISO 9001:2015, Good Laboratory Practice (GLP), Good Clinical Practice (GCP), and Good Manufacturing Practice (GMP) standards. Their service portfolio is extensive, covering discovery and surveillance for viral and bacterial pathogens, as well as dedicated research into antimicrobial resistance (AMR) to address drug toxicity and multi-drug resistant infections. In the pre-clinical phase, VDEC offers in vivo model development, efficacy testing, and advanced imaging services like MRI and PET-CT. Their clinical services include the validation of immunoassays for Phase I through III trials and high-throughput serology. Additionally, they provide data for regulatory submissions during the post-licensure phase and offer biosafety training for outbreak responses. While the provided text is an overview of services rather than a regulatory inspection report—and thus does not list specific violations or inspection dates—it serves as a guide for organizations requiring accredited laboratory and manufacturing support. To utilize these services, interested organizations are encouraged to contact the UKHSA directly to discuss collaborative research and development needs.